NASDAQ · NURO
Healthcare · Medical - Devices
$4.58
Up+$0.22 (+5.05%)
Updated Sep 11, 2026, 12:42 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NURO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning NURO.
NURO research
Company profile and research snapshot.
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · May 2, 2025
electroCore, Inc. has completed the acquisition of NeuroMetrix, Inc., gaining access to the Quell platform and positioning itself as a leader in non-invasive bioelectronic technologies for chronic pain and wellness markets.
GlobeNewswire Inc. · Aug 13, 2024
NeuroMetrix, a healthcare company, is engaged in a strategic review process to enhance shareholder value. The company has evaluated multiple opportunities but determined that none were in the best interests of shareholders at this time. NeuroMetrix has implemented cost-cutting measures and is in discussions to sell certain international assets.
GlobeNewswire Inc. · Apr 19, 2024
NeuroMetrix today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders.
GlobeNewswire Inc. · Mar 14, 2024
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NURO.
No results
No recent SID articles mention NURO.
